Skip to main content
. 2023 Sep 16;9(9):e20110. doi: 10.1016/j.heliyon.2023.e20110

Table 2.

Summary of PRO measures at baseline and during follow-up.

Pre-ETI mean (SD), n = 22 Day 14 mean (SD), n = 21 Day 28 mean (SD), n = 21 Day 42 mean (SD), n = 22 Day 56 mean (SD), n = 20 Day 70 mean (SD), n = 21 Day 84 mean (SD), n = 21 Day 98 mean (SD), n = 20
Pain intensity T-score 35.9 (6.76) 35.6 (6.63) 37.3 (6.60) 35.1 (5.27) 34.0 (3.77) 34.8 (4.81) 35.1 (5.19) 35.1 (5.80)
Pain interference T-score 44.7 (7.29) 46.5 (9.83) 45.9 (6.32) 43.6 (4.93) 42.1 (3.15) 43.3 (4.97) 42.2 (3.93) 44.2 (5.54)
FACIT Fatigue 37.4 (7.48) 39.8 (5.29) 40.7 (5.38) 40.6 (6.89) 41.4 (5.08) 40.2 (6.11) 40.6 (5.41) 40.3 (5.69)
SNOT22 Sinus symptoms 21.7 (16.91) 14.4 (10.66) 13.4 (11.78) 15.5 (13.24) 14.2 (14.23) 14.2 (11.10) 13.8 (12.79) 12.7 (11.32)
PAC-SYM Constipation 5.6 (5.26) 5.1 (4.79) 4.9 (5.59) 5.1 (5.88) 5.4 (6.10) 4.2 (4.88) 4.5 (5.80) 4.5 (5.55)
PHQ8 Depression 4.9 (5.27) 3.3 (3.09) 3.8 (3.91) 3.6 (4.56) 2.9 (3.30) 4.3 (4.57) 3.7 (3.87) 3.4 (3.70)
GAD7 Anxiety 4.1 (5.44) 3.0 (3.68) 3.2 (3.69) 2.5 (3.16) 3.3 (4.60) 3.0 (3.58) 3.0 (3.43) 3.1 (3.46)
PSQI Sleep Quality 7.1 (3.31) 6.2 (3.02) 5.6 (3.08) 5.6 (3.23) 4.8 (2.23) 4.6 (2.50) 4.9 (2.61) 4.9 (2.39)